Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin expression of 110% ...

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics ...

Physical therapy can help maintain muscle ... MedlinePlus. DMD gene. MedlinePlus. Duchenne muscular dystrophy. National Human Genome Research Institute. About Duchenne muscular dystrophy.

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

best-in-class Duchenne muscular dystrophy gene therapy candidate — — Encouraging early signals of potential cardiac benefit observed — —SGT-003 has been well-tolerated in the 6 ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.